IBL-302

IBL-302

• CAS Number: 1414455-21-2
• UNSPSC Description: IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629)[1][2][3].
• Target Antigen: Akt; mTOR; PI3K; Pim
• Type: Reference compound
• Related Pathways: JAK/STAT Signaling;PI3K/Akt/mTOR
• Applications: Cancer-Kinase/protease
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/ibl-302.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: CC1=C(C(C=C2N[S](=O)(C(C=C3)=C4)=O)=CN=C2OC)SC5=C1N=CN=C5C6=CC=C(CNC(C4=C3F)=O)S6
• Molecular Weight: 567.63
• References & Citations: [1]Kennedy SP et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020 Apr;39(14):3028-3040.|[2]Martínez-González S, et al. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. ACS Med Chem Lett. 2021 Nov 2;12(11):1794-1801.|[3]Kennedy S P, et al. Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models[J]. Cancer Research, 2018, 78(13_Supplement): 2932-2932.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported